Literature DB >> 33244490

AN ADJUNCTIVE USE OF ASFOTASE ALFA AND ZOLEDRONIC ACID AFTER SPINAL SURGERY IN NEUROFIBROMATOSIS TYPE 1 RELATED DYSTROPHIC SCOLIOSIS.

Tasma Harindhanavudhi, Takashi Takahashi, Anna Petryk, David W Polly.   

Abstract

OBJECTIVE: Dystrophic scoliosis is a serious skeletal manifestation of neurofibromatosis 1 (NF1). The condition requires surgical intervention that is frequently associated with poor outcome due to the high rate of impaired bone healing, pseudoarthrosis, and loosening of the spinal instrumentation. New therapeutic approaches are needed to improve surgical outcomes.
METHODS: Clinical, laboratory, and radiographic data are presented.
RESULTS: A 54-year-old woman with severe NF1 related dystrophic scoliosis and 3 prior surgical interventions underwent revision of lumbar fusion with intraoperative recombinant human bone morphogenetic protein (rhBMP-2) for loosening and a fracture of the left vertical rod at the L4 pedicle screw connection. Two days after surgery, a computed tomography (CT) scan revealed a left posterior iliac periscrew fracture. Given a high risk of mechanical failure, zoledronic acid and asfotase alfa were also administered at 3 and 7 months after surgery. At 14 months after surgery, back pain improved, and a CT scan showed stable spinal fusion and a healed left posterior iliac screw fracture.
CONCLUSION: Combination therapy including asfotase alfa with rhBMP-2 and bisphosphonate resulted in solid arthrodesis after spinal surgery in NF1-related dystrophic scoliosis.
Copyright © 2020 AACE.

Entities:  

Year:  2020        PMID: 33244490      PMCID: PMC7685405          DOI: 10.4158/ACCR-2020-0222

Source DB:  PubMed          Journal:  AACE Clin Case Rep        ISSN: 2376-0605


  15 in total

Review 1.  Pathophysiology of neurofibromatosis type 1.

Authors:  Amy Theos; Bruce R Korf
Journal:  Ann Intern Med       Date:  2006-06-06       Impact factor: 25.391

Review 2.  The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2.

Authors:  D H Gutmann; A Aylsworth; J C Carey; B Korf; J Marks; R E Pyeritz; A Rubenstein; D Viskochil
Journal:  JAMA       Date:  1997-07-02       Impact factor: 56.272

3.  Treatment of congenital pseudarthrosis of the tibia with recombinant human bone morphogenetic protein-7 (rhBMP-7). A report of five cases.

Authors:  Francis Young-In Lee; Stefano M Sinicropi; Fred Suin Lee; Michael G Vitale; David P Roye; In Ho Choi
Journal:  J Bone Joint Surg Am       Date:  2006-03       Impact factor: 5.284

4.  Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia.

Authors:  Priya S Kishnani; Cheryl Rockman-Greenberg; Frank Rauch; M Tariq Bhatti; Scott Moseley; Andrew E Denker; Eric Watsky; Michael P Whyte
Journal:  Bone       Date:  2018-12-18       Impact factor: 4.398

5.  Modulation of spinal deformities in patients with neurofibromatosis type 1.

Authors:  A A Durrani; A H Crawford; S N Chouhdry; A Saifuddin; T R Morley
Journal:  Spine (Phila Pa 1976)       Date:  2000-01       Impact factor: 3.468

6.  Enzyme-replacement therapy in life-threatening hypophosphatasia.

Authors:  Michael P Whyte; Cheryl R Greenberg; Nada J Salman; Michael B Bober; William H McAlister; Deborah Wenkert; Bradley J Van Sickle; Jill H Simmons; Terence S Edgar; Martin L Bauer; Mohamed A Hamdan; Nick Bishop; Richard E Lutz; Mairead McGinn; Stanley Craig; Jean N Moore; John W Taylor; Robert H Cleveland; William R Cranley; Ruth Lim; Tom D Thacher; Jill E Mayhew; Matthew Downs; José Luis Millán; Alison M Skrinar; Philippe Crine; Hal Landy
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

7.  Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions.

Authors:  Feng-Chun Yang; Shi Chen; Alexander G Robling; Xijie Yu; Todd D Nebesio; Jincheng Yan; Trent Morgan; Xiaohong Li; Jin Yuan; Janet Hock; David A Ingram; D Wade Clapp
Journal:  J Clin Invest       Date:  2006-10-19       Impact factor: 14.808

8.  Preliminary experience with the combined use of recombinant bone morphogenetic protein and bisphosphonates in the treatment of congenital pseudarthrosis of the tibia.

Authors:  Oliver Birke; Aaron Schindeler; Manoj Ramachandran; Chris T Cowell; Craig F Munns; Michael Bellemore; David G Little
Journal:  J Child Orthop       Date:  2010-10-21       Impact factor: 1.548

9.  Decreased bone mineral density in patients with neurofibromatosis 1.

Authors:  Marga Lammert; Martin Kappler; Victor-Felix Mautner; Kurt Lammert; Stephan Störkel; Jan M Friedman; Derek Atkins
Journal:  Osteoporos Int       Date:  2005-06-30       Impact factor: 4.507

Review 10.  Orthopaedic manifestations of neurofibromatosis type 1.

Authors:  David S Feldman; Charles Jordan; Lauren Fonseca
Journal:  J Am Acad Orthop Surg       Date:  2010-06       Impact factor: 3.020

View more
  1 in total

1.  A Pre-clinical Standard Operating Procedure for Evaluating Orthobiologics in an In Vivo Rat Spinal Fusion Model.

Authors:  Andrew L Alejo; Scott McDermott; Yusuf Khalil; Hope C Ball; Gabrielle T Robinson; Ernesto Solorzano; Amanda M Alejo; Jacob Douglas; Trinity K Samson; Jesse W Young; Fayez F Safadi
Journal:  J Orthop Sports Med       Date:  2022-09-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.